A French SME is looking for companies providing preclinical services in cardiovascular pathologies

Summary

Profile type	Company's country	POD reference
Business request	**France**	**BRFR20251010013**
Profile status	**Type of partnership**	**Targeted countries**
PUBLISHED	**Supplier agreement**	**• World**
Contact Person	**Term of validity**	**Last update**
Marcin MERCHEL	**13 Oct 2025** **13 Oct 2026**	**13 Oct 2025**

General Information

Short summary

A French start-up is developing therapeutic molecules to protect the heart and other organs from cell death after injury. Following a successful proof-of-concept study showing the efficacy of the lead molecule for the treatment of myocardial infarction, the company is now seeking partners for preclinical regulatory evaluation (toxicology, safety, large species), formulation of the molecule, and clinical trial design.

Full description

A French start-up is developing cutting-edge therapeutic molecules targeting cell death mechanisms triggered by oxygen deprivation in organs, particularly during acute myocardial infarction.
Management of patients by the interventional cardiologist consists of reopening the coronary artery occluded during the heart attack. Unfortunately, instead of providing only benefits to save the patients, the sudden influx of oxygen can paradoxically activate cell death in vulnerable heart tissue. The company’s therapeutic innovation lies in inhibiting these harmful adverse effects, offering protection not only to the heart but also to other organs affected by ischemic injury, such as in stroke or organ transplantation. A proof-of-concept study has already demonstrated the efficacy of the lead molecule in treating myocardial infarction.

The start-up is now seeking European partners to perform preclinical regulatory evaluation (toxicology, safety, large species), formulation of the therapeutic molecule, and clinical design. Only suppliers that are capable of contributing

to the development of a blockbuster drug will be considered. High standards in quality control are also essential for subcontracting.

Advantages and innovations

Technical specification or expertise sought

Partner for the experiment on a large animal model: The partner, a service provider or a platform, should have strong expertise in ischemia-reperfusion injury in the pig model and must have experience in large animal surgery with a protocol and experimental setup similar to that of the clinic (angioplasty balloon, MRI). To do this, he must have participated in several preclinical studies for big pharma that have provided validation (publication, medicine development, patent, etc.). The protocol used for evaluating the lead molecule should mimic the procedure used in the catheter laboratory by an interventional cardiologist.

Partner for regulatory pre-clinical studies: The partner, a service provider accepted by the FDA/EMA, must have expertise in the analysis of a peptide-based molecule for pharmacological and toxicity (genetic or general) studies.

Partner for IND and clinical trial: The partner, a service provider accepted by the FDA/EMA, must have expertise in parallel interaction between the EMA and FDA to obtain the required authorization to perform clinical trials.

Partner for drug formulation: The partner, a service provider, must have expertise in pre-formulation characterization studies, including accelerated stability (stress) studies, stability-indicating analytical method development, and other physicochemical characterizations designed to pinpoint potential product candidate stability problems and enable formulation optimization.

Stage of development

Available for demonstration

IPR Status

IPR granted

IPR Notes

Sustainable Development goals

- **Goal 3: Good Health and Well-being**

Partner Sought

Expected role of the partner

The partner must be a service provider. It must have quality certification in its field, particularly regarding preclinical regulatory requirements:

Experimentation on a large animal model: The partner should have strong expertise in ischemia-reperfusion injury in the pig model and must be experienced in large animal surgery with a protocol and experimental setup similar to that of the clinic. To do this, he must have participated in several preclinical studies for big pharma that have provided validation (publication, medicine development, patent, etc.). The protocol used for evaluating the lead molecule should mimic the procedure used in the catheterization laboratory by an interventional cardiologist.

Regulatory pre-clinical studies: The partner, a service provider accepted by the FDA/EMA, must have the expertise in the analysis of a peptide-based molecule for pharmacological and toxicity (genetic or general) studies.

IND (Investigational New Drug) and clinical trial: The partner, a service provider accepted by the FDA/EMA, must have expertise in parallel interaction between the EMA and FDA to obtain the required authorization to perform clinical trials.

Drug formulation: The partner, acting as a service provider, must demonstrate expertise in pre-formulation characterization studies, including accelerated stability (stress) testing, the development of stability-indicating analytical methods, and various physicochemical characterizations aimed at identifying potential stability issues in the product candidate and supporting formulation optimization.

Type of partnership

Supplier agreement

Type and size of the partner

- **SME 50 - 249**
- **Big company**
- **SME 11-49**

Dissemination

Technology keywords

- **06001002 - Clinical Research, Trials**
- **06001015 - Pharmaceutical Products / Drugs**
- **06001011 - Heart and blood circulation illnesses**

Market keywords

- **09003001 - Engineering services**
- **05005022 - Other clinical medicine**

Targeted countries

- **World**

Sector groups involved

- **Health**